記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.21037/tlcr-2025-739

Web of Science

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.3390/cancers17040641

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.

DOI： 10.1111/cga.12588

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本口腔ケア学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

DOI： 10.1002/osi2.1202

Web of Science

researchmap

記述言語：日本語   出版者・発行元：(一社)日本緩和医療薬学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

PURPOSE: Oral mucositis is a severe adverse event in patients with head and neck cancer (HNC) receiving chemotherapy and radiotherapy that may cause the termination of cancer treatment. In this study, we aimed to reveal the benefits of pharmacist interventions in oral health care for patients with HNC receiving concurrent chemoradiotherapy (CCRT). METHODS: We conducted a multicenter, prospective cohort study on 173 patients from September 2019 to August 2022. We evaluated the association between the occurrence of oral mucositis during CCRT and various factors in the absence or presence of direct medication instructions from hospital pharmacists. RESULTS: Sixty-eight patients received medication instructions from pharmacists (the pharmacist intervention group), whereas 105 patients did not receive instructions (the control group). Logistic regression analysis showed that grade 2 (Gr 2) oral mucositis was significantly lower in patients receiving pharmacist interventions than in patients in the control group (adjusted odds ratio [aOR], 0.42; 95% confidence interval [CI], 0.18-0.96; P = 0.04). The time to onset of Gr 2 oral mucositis was significantly longer in the pharmacist intervention group than in the control group (hazard ratio, 0.53; 95% CI, 0.29-0.97; P = 0.04). CONCLUSION: Direct intervention, especially when provided by hospital pharmacists, can have a real effect in supporting patients with HNC experiencing severe side effects of treatments. Moreover, the integration of pharmacists into the oral healthcare team is becoming even more essential to reduce the severity of side effects.

DOI： 10.1007/s00520-023-07784-6

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J04451&link_issn=&doc_id=20230511280012&doc_link_id=%2Fdg4hppha%2F2023%2F005905%2F012%2F0519-0524%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg4hppha%2F2023%2F005905%2F012%2F0519-0524%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本医療薬学会  

ヒト免疫不全ウイルス(HIV)の外来診療における協働意思決定に基づいた継続的な薬剤師面談の有効性を評価した。2016年10月～2018年3月の間に当院HIV外来を定期受診した抗レトロウイルス療法(ART)継続中の患者49名を対象とした。このうち、処方変更が不要であると判断された11名(男性10名、女性1名、中央値48歳)を変更提案不要群、薬剤師面談において処方変更を提案した38名(男性30名、女性8名、中央値45.5歳)を変更提案群、変更提案群のなかで処方変更がなされた35名を変更群と定義した。ARTの錠数、併用服薬錠数、服薬総錠数、服薬種類数は処方変更後に有意に減少し、推奨ART、single table regimenの適応となった患者数は有意に増加した。ART変更理由は、多い順に副作用・長期毒性の回避・軽減、服薬負担軽減、薬物相互作用回避、薬価負担軽減であった。継続的な薬剤師面談によって、治療安全性の向上、服薬アドヒアランス維持、経済的負担軽減が得られることが示唆された。

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J03520&link_issn=&doc_id=20230216220001&doc_link_id=%2Fdb5pharm%2F2023%2F004902%2F001%2F0039-0050%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdb5pharm%2F2023%2F004902%2F001%2F0039-0050%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本医薬品安全性学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品安全性学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本緩和医療薬学会  

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

Although the dosage of oral antibiotics (OA) for the mandibular third molar extraction (MTME) varies among the administration periods according to the current guideline, our previous reports suggested that it might be possible to further shorten the administration period without increasing the incidence of surgical site infection (SSI). In the present study, we retrospectively evaluated the relationship between the incidence of SSI and the administration period of OA in patients who underwent the MTME in our hospital. This retrospective cohort study included 348 patients who underwent the MTME in our dental outpatient clinic from June 2020 to March 2022. The administrated antibiotic was amoxicillin (AMPC) in all patients. Patients were divided into two groups based on the administration period of AMPC single and three times before the surgery. The following information was collected: (1) patient factors (age, gender, body mass index, diagnosis, mandibular third molar status); (2) surgical factors (operation time, presence/absence of wound closure, presence/absence of hemostat, experience of surgeons); (3) relationship between administration period of OA and SSI occurrence; and (4) details of SSI. There were 217 cases in the single group and 131 cases in the three times group. The incidence of SSI was 1.1% (4/348), with 1.4% (3/217) in the single group and 0.8% (1/131) in the three times group; there was no significant difference between the two groups. Our result suggests that single administration of AMPC before the MTME would be sufficient for the prevention of SSI in Japanese patients without risk factors.

DOI： 10.1248/yakushi.22-00163

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Oral mucositis (OM) is a common side effect in patients with cancer receiving chemotherapy and radiotherapy; however, no salivary mediator is known to be associated with OM. We aimed to determine candidate salivary inflammatory mediators potentially associated with OM in patients with cancer. To this end, we compared the relationships between OM grade, oral mucosal dryness, and inflammatory mediators (Interleukin (IL)-1β, IL-6, IL-10, IL-12p70, tumor necrosis factor (TNF), prostaglandin E2, and vascular endothelial growth factor) in patients with cancer and in healthy volunteers (HV). We collected saliva samples from 18 patients with cancer according to the following schedule: 1) within 14 days of treatment initiation, 2) within 3 days of OM occurrence, 3) when OM was improved or got worsened, and 4) within 7 days after chemotherapy completion. The oral care support team determined the OM grade at each sample collection point based on CTCAE version 5.0. Salivary inflammatory mediator concentrations were detected using cytometric bead array or enzyme-linked immunoassay. We compared oral mucosal dryness in pre- and post-index patients with cancer to that in HV (n = 33) using an oral moisture-checking device. Fourteen of eighteen patients experienced OM (four, grade 3 OM; four, grade 2 OM; six, grade 1 OM). IL-6, IL-10, and TNF salivary concentrations were significantly increased in the post-index group compared to those in the pre-index group (p = 0.0002, p = 0.0364, and p = 0.0160, respectively). Additionally, salivary IL-6, IL-10, and TNF levels were significantly higher in the post-index group than in the HV group (p < 0.0001, p < 0.05, and p < 0.05, respectively). Significant positive correlations were observed between OM grade and salivary IL-6, IL-10, and TNF levels (p = 0.0004, r = 0.4939; p = 0.0171, r = 0.3394; and p = 0007, r = 0.4662, respectively). Oral mucosal dryness was significantly higher in the HV than in the pre- and post-index groups (p < 0.001). Our findings suggest that salivary IL-6, IL-10, and TNF levels may be used as biomarkers for OM occurrence and grade in patients with cancer. Furthermore, monitoring oral mucosal dryness and managing oral hygiene before cancer treatment is essential.

DOI： 10.1371/journal.pone.0267092

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: According to the guidelines, the dosage for mandibular wisdom tooth extraction (MWTE) varies within the administration period. There is a 24-fold difference between the minimum and maximum doses. If an appropriate antimicrobial can be administered without increasing incidence of surgical site infection (SSI), it may lead to a global action plan on antimicrobial resistance (AMR). Therefore, we prospectively surveyed incidence of SSI post-operatively and use of oral antibiotics (OA) for MWTE. METHODS: Subjects were patients who underwent MWTE in our dental outpatient clinic from May 2019 to April 2020. Two groups were formed depending on type of administration period they received: 24 h and 48 h after surgery. The following information was collected: (1) patient factors (age, gender, body mass index, presence/absence of preoperative medication, diagnosis, impacted wisdom tooth status; (2) surgical factors (operative time, presence/absence of closure, presence/absence of hemostat, doctor career, type and frequency of painkiller); (3) relationship between administration period of OA and SSI occurrence; and (4) details of SSI. RESULTS: Three hundred forty subjects were analyzed, all of which used amoxicillin. There were 106 cases in 24 h group and 234 cases in 48 h group. The total incidence of SSI was 1.1% (4/340 cases), with 0.9% (1/106 cases) in 24 h group and 1.3% (3/234 cases) in 48 h group; there was no difference between the two groups. CONCLUSION: Our study suggests that amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery) might be sufficient in preventing SSI in Japanese dental patients without SSI risk factors.

DOI： 10.1016/j.jiac.2021.01.018

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: We investigated the use of oral antibiotics (OA) and surgical site infection (SSI) related to extractions of ordinary teeth and mandibular wisdom teeth in a dental outpatient clinic from January 2015 to December 2019. METHODS: The following information were surveyed: (1) presence/absence of OA, (2) timing, (3) type, (4) administration period, and (5) SSI rates. RESULTS: The use of OA during ordinary tooth extraction decreased from 68.3% to 41.3%, but SSI rate did not change during this period of time. Total SSI rate was 0.8% (122/14,832) on average. For mandibular wisdom tooth extraction, preoperative administration of third-generation cephalosporins decreased from 70.4% to 0.3% while that of penicillin (AMPC) increased from 0% to 98%. SSI rate was not changed after these improvements. Total SSI rate was 3.5% (180/5106) on average. The duration of OA was slightly decreased to two days in 2018 and 2019, and it was found that there was no significant difference in SSI rates between 2- and 3-day durations. Preoperative administration had 0.37 odds ratio (OR) (95% confidence interval (95%CI): 0.22-0.63) of SSI compared with postoperative administration. AMPC had 0.76 OR (95% CI: 0.55-1.04) of SSI compared with Third-generation cephalosporins and others. Timing of OA was P < 0.01. CONCLUSIONS: SSI rates did not change over time, administration period of OA decreased and the use of AMPC increased. Therefore, it seems necessary to continue to investigate the effects of SSI risk factors proactively in the future and to make efforts in the advocacy of appropriate antimicrobial use.

DOI： 10.1016/j.jiac.2020.08.022

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

OBJECTIVES: This retrospective study examined how a pharmacist-involved education program in a multidisciplinary team (PEMT) for oral mucositis (OM) affected head-and-neck cancer (HNC) patients receiving concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Total samples data of 53 patients during the stipulated timeframe were retrospectively collected from electronic medical records from February 2017 to January 2019. We compared the presence/absence of OM (OM: yes/no) between patients with and without PEMT (PEMT: yes/no) as the primary endpoint and OM severity as the secondary endpoint. The following information was surveyed: age, gender, weight loss, steroid or immunosuppressant use, hematological values (albumin, white blood cell count, blood platelets, and neutrophils), cancer grade, primary cancer site, type and use of mouthwash and moisturizer, opioid use (yes/no, days until the start of opioid use, and dose, switch to tape), and length of hospital day (LOD). The two groups were compared using Fisher's exact test for qualitative data and the Mann-Whitney U test for quantitative data, and a significance level of p<0.05 was set. RESULTS: The group managed by PEMT had significantly lower weight loss and a significantly lower incidence of local anesthetic and opioid use and switch to tape compared with the group not managed by PEMT (p<0.05). The two groups showed no significant difference in OM (yes/no) or OM severity. The PEMT group had significantly shorter LOD at 57 (53-64) days compared with the non-PEMT group at 63.5 (57-68) days (p<0.05). CONCLUSIONS: Our results showed that PEMT did not improve OM (yes/no) or OM severity in HNC patients undergoing CCRT. However, the PEMT group had a lower incidence of grades 3 and 4 OM than the non-PEMT group, although not significantly. In addition, PEMT contributed to oral pain relief and the lowering of the risk for OM by reduction in weight loss.

DOI： 10.1371/journal.pone.0260026

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

Introduction: Postoperative infection is a major cause of morbidity and prolonged hospitalization in patients undergoing gastrointestinal surgery. This observational study aimed to investigate the risk factors associated with postoperative infection and to develop a prediction model for postoperative infections that occur after gastrointestinal surgery. Methods: The study population comprised 1637 patients who underwent gastrointestinal surgery at Niigata University Medical and Dental Hospital between June 2013 and May 2017. Observational data from 1883 surgical procedures were used in the statistical analyses (including 198 patients who underwent several operations). Results: The generalized estimating equation (GEE) was used to detect significant risk factors, including older age, history of smoking, body temperature greater than 38 °C, non-endoscopic surgical procedures, surgery in the thoracic or lower gastrointestinal tract, and use of medical nutritional products during surgery. The sensitivity and specificity of the GEE model were 88.2% and 55.1%, respectively. Conclusion: This study established a predictable GEE model, incorporating the data of patients who were hospitalized several times into a prediction analysis, even though the sensitivity was not sufficiently high. The GEE model, which is considered clinically useful, can be constructed using a variety of variables, including those obtained from electronic health records.

DOI： 10.3390/gastroent11020007

researchmap

記述言語：英語  

Severe hepatotoxicity from combination chemotherapy with cisplatin and 5-fluorouracil is a rare adverse effect. In this case report, we present a case with severe hepatotoxicity immediately following chemotherapy with cisplatin and 5-fluorouracil. This female patient had previously been treated with this combination with no hepatotoxicity. The elevated liver enzymes quickly normalized after chemotherapy was stopped. There were no specific changes in liver imaging. As hepatotoxicity occurred after repeated administration of cisplatin, we suggest that this hepatotoxicity might represent a case of allergic hepatitis caused by cisplatin. Severe hepatotoxicity should be watched for with repeated administration of cisplatin.

DOI： 10.1007/s13691-019-00394-2

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: Because of the increasing age of the general population, there is an increasing number of older patients with lung cancer. Cancer chemotherapy often causes severe hematological toxicity in older patients. OBJECTIVE: This study aimed to explore the risk factors affecting the hematological toxicity of cytotoxic anticancer drugs in patients with lung cancer. METHODS: Data were retrospectively collected from 194 patients with lung cancer at Niigata University Medical and Dental Hospital, Japan, between April 2011 and March 2016, when the patients underwent their first round of cytotoxic chemotherapy. The patients were divided into three groups on the basis of age: <65, 65-74, and ≥75 years. Physiological functions and laboratory data before treatment, as well as hematological adverse events following chemotherapy, were compared among the groups. RESULTS: Patients aged ≥75 years were significantly more likely to experience grade 3 or 4 neutropenia, compared with patients aged <65 years. However, there were no differences in the incidence of anemia or thrombocytopenia among the age groups. The frequency of febrile neutropenia tended to increase with age. Multivariate analysis showed that age ≥75 years, male sex, and a performance status of ≥2 were independent factors for grade 3 or 4 neutropenia. Patients with 2 or 3 of these factors had a significantly higher frequency of neutropenia, compared with patients who had 0 or 1 of these factors. CONCLUSION: We found that age ≥75 years, male sex, and a performance status of ≥2 were independent risk factors for grade 3 or 4 neutropenia.

DOI： 10.1159/000507864

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)医薬品相互作用研究会  

当院歯科領域では周術期患者に対し、術後感染予防として注射用抗菌薬セファゾリン(CEZ)が推奨されているが、CEZ投与終了翌日から経口抗菌薬へ切り替えて投与する治療(経口スイッチ療法)が経験的に行われる場合がある。「術後感染予防抗菌薬適正使用のための実践ガイドライン」では、推奨投与期間を超えた経口抗菌薬の追加は不要であるとされている。そこで今回、経口スイッチ療法の必要性について検討するため、2015年1月～6月に当院歯科領域でCEZを使用された患者213例を対象とし、経口スイッチ療法実施群(111例)と非実施群(102例)に分けて諸データの群間比較を行った。結果、実施群の背景として、「入院期間の短縮」や「剤形変更による費用削減」などを期待して経口スイッチ療法が行われていたと考えられたが、実際には「入院期間の短縮」「費用削減」とも認められなかった。このことから経口スイッチ療法の必要性は低い可能性が示唆された。

researchmap

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2017&ichushi_jid=J04451&link_issn=&doc_id=20170612190005&doc_link_id=%2Fdg4hppha%2F2017%2F005306%2F002%2F0671-0674%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg4hppha%2F2017%2F005306%2F002%2F0671-0674%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

OBJECTIVES: The adenosine triphosphate assay using peripheral lymphocytes may be useful to evaluate the risks of acute rejection and infection in kidney transplant patients. We used the adenosine triphosphate assay to evaluate differences between recipients who were treated with cyclosporine- or tacrolimus-based immunosuppressive therapy. MATERIALS AND METHODS: Adenosine triphosphate levels were measured in peripheral CD4+ cells before and after transplant and were correlated with clinical outcomes in 45 kidney transplant recipients. These recipients received immunosuppressive therapy with either cyclosporine (23 patients) or tacrolimus (22 patients). RESULTS: Adenosine triphosphate levels were significantly lower in the cyclosporine- than tacrolimus-based therapy groups from 2 to 6 weeks after transplant. Adenosine triphosphate levels were similar between these groups before and 1 week after transplant. The frequency of cytomegalovirus infection was greater in the recipients who received cyclosporine (17 patients [74%]) than tacrolimus (6 patients [27%]; P ≦ .003). The frequency of acute rejection episodes was similar between the cyclosporine and tacrolimus groups. CONCLUSIONS: These observations suggest that cyclosporine-based immunosuppressive therapy causes excessive immunosuppression compared with tacrolimus-based therapy, evidenced by the lymphocyte adenosine triphosphate levels. The adenosine triphosphate assay using peripheral CD4+ cells may be a useful method for predicting the occurrence of cytomegalovirus infections in kidney transplant recipients.

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lymphocyte immunosuppressant sensitivity test (LIST) with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay procedure has been used to predict the pharmacological efficacy of immunosuppressive agents to prevent acute rejection episodes for renal transplant recipients. In this study, mycophenolic acid (MPA) pharmacological efficacies were evaluated by LIST at both prior to and just after renal transplantation. We compared the efficacies to the clinical outcome of these recipients. MPA's pharmacological efficacy was evaluated by LIST not only before the operation but also at 2, 4, and 6 weeks after transplantation in 16 renal transplant recipients. These recipients were divided into high- and low-sensitivity groups according to peripheral blood mononuclear cell (PBMC) sensitivity to MPA in vitro. The MPA sensitivities were compared to cytomegalovirus (CMV) infection and acute rejection episodes in these recipients under MPA immunosuppressive therapy. The rate of CMV infection episodes in the low-MPA pharmacological efficacy group categorized at 2 weeks after renal transplantation was 5/6 (83.3%), which was significantly higher than the rate of 1/10 (10.0%) (p < 0.01) in the high-MPA sensitivity group. However, the MPA pharmacological efficacy evaluated both before and after transplantation had no relationship with the incidence of rejection episodes. These findings suggest that the MPA pharmacological efficacy evaluated by LIST at 2 weeks after operation is a useful biomarker for predicting the following occurrence of CMV infection episodes in renal transplant recipients.

DOI： 10.3727/215517913X674216

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lymphocyte immunosuppressant sensitivity test (LIST) using patient peripheral lymphocytes can predict the therapeutic efficacy of immunosuppressive drugs used in renal transplantation. We have evaluated the pharmacological efficacy of drugs by using the LIST with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, which measures the cellular mitochondrial activity. The LIST with the MTT assay requires a relatively large amount of blood. As such, we developed a new assay for examining drug sensitivity with a CellTiter-Glo assay, which measures the amount of cellular ATP to help increase the assay's sensitivity and reduce the amount of blood needed. Renal transplant recipients generally receive either cyclosporine or tacrolimus, in addition to mycophenolate mofetil and methylprednisolone, as an immunosuppressive therapy to prevent acute rejection. We evaluated the pharmacological efficacy of these immunosuppressive agents with both the MTT and CellTiter-Glo assays using the peripheral blood mononuclear cells of 21 healthy volunteers. Furthermore, we also examined the relationship between these immunosuppressive agents' pharmacological efficacy and the results of the MTT and CellTiter-Glo assays. The IC50 values for cyclosporine, tacrolimus, mycophenolic acid, and methylprednisolone were significantly correlated between the MTT and CellTiter-Glo assays. The amount of blood cells required for LIST with the CellTiter-Glo assay was able to be reduced to 25% of the amount required for the previously established LIST with the MTT assay procedure. We concluded from these observations that the LIST with the CellTiter-Glo assay should be used instead of the MTT assay for carrying out individualized immunosuppressive therapy in renal transplantation patients.

DOI： 10.3727/215517913X674207

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lymphocyte immunosuppressant sensitivity test (LIST) with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay procedure can predict the pharmacological efficacy of immunosuppressive agents. A previous study reported the pharmacological efficacy of tacrolimus evaluated by LIST just before renal transplantation significantly correlated with the incidence of acute rejection episodes. However, the pharmacological efficacy of tacrolimus has not been estimated after renal transplantation. Therefore, the present study evaluated the pharmacological efficacy of tacrolimus by LIST using the MTT assay procedure before and 1, 3, and 12 months after transplantation in 17 renal transplant recipients that received tacrolimus-based immunosuppressive therapy. The tacrolimus pharmacological efficacies before and after the procedure were also compared with incidence of acute rejection and cytomegalovirus (CMV) infection episodes. The individual values of tacrolimus 50% inhibition of lymphocyte proliferation (IC50) varied widely before transplantation, and the mean value of the IC50 was 126.4 ± 337.7 ng/ml. The patients were divided into two groups according to the tacrolimus IC50 values evaluated before transplantation. The rate of acute rejection episodes in the tacrolimus high-sensitivity group was significantly lower than that in the tacrolimus low-sensitivity group (p = 0.005). The tacrolimus IC50 deviation between patients expanded further at one and three months after surgery. However, the sensitivity deviation almost converged at 1 year after surgery. Moreover, the pharmacological efficacy of tacrolimus evaluated at 1, 3, and 12 months after transplantation did not significantly correlate with the incidence of acute rejection episodes. The pharmacological efficacies of tacrolimus evaluated at both before and after surgery were not significantly correlated with the episodes of CMV infection. These findings suggest that the pharmacological efficacy of tacrolimus evaluated with LIST before surgery is a useful biomarker for predicting the occurrence of acute allograft rejection in renal transplantation.

DOI： 10.3727/215517912X639360

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Basiliximab is a recently developed immunosuppressive agent for the prevention of acute allograft rejection in renal transplant recipients. The combination use of basiliximab and a calcineurin inhibitor was suggested to be more effective in comparison to immunosuppressive therapy using calcineurin inhibitor without basiliximab. Cyclosporine has been generally administered with basiliximab for renal transplant recipients. However, in cases of tacrolimus-based immunosuppressive regimen, the clinical efficacy and safety of combined use of tacrolimus and basiliximab remains to be elucidated. This study evaluated the tacrolimus pharmacological efficacy using a lymphocyte immunosuppressant sensitivity test (LIST) with MTT assay procedures in 16 cases of renal transplant recipients treated by tacrolimus without basiliximab and in 13 cases treated by tacrolimus in combination with basiliximab. The rate of acute rejection episodes in the recipients treated with tacrolimus plus basiliximab was 1/13 (7.7%), whereas the rate in the recipients treated with tacrolimus without basiliximab was 6/16 (37.5%). The recipients were divided into two groups according to their peripheral blood mononuclear cell (PBMC) sensitivity to tacrolimus [i.e., including a tacrolimus high sensitivity group (IC(50) <1.0 ng/ml) and a low sensitivity group (IC(50) >1.0 ng/ml). In the recipients treated with tacrolimus without basiliximab, the rate of acute rejection episodes in the tacrolimus high sensitivity group was 1/10 (10.0%), which was significantly lower than the rate in the low sensitivity group of 5/6 (83.3%; p = 0.008). The incidence of cytomegalovirus infection was not significantly different between the tacrolimus high and the low sensitivity groups of the recipients treated with tacrolimus with and without basiliximab. Therefore, in the case of selected tacrolimus-based immunosuppressive therapy for renal transplant recipients, the tacrolimus pharmacological efficacy should be evaluated using LIST at a time just before the transplant procedure in order to accurately predict allograft rejection. The data also suggested that low tacrolimus sensitivity recipients should be treated with tacrolimus-based immunosuppressive therapy in combination with basiliximab.

DOI： 10.3727/096368911X605493

PubMed

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

It is obvious that pharmacists play a critical role as risk managers in the healthcare system, especially in medication treatment. Hitherto, there is not a single multicenter-survey report describing the effectiveness of clinical pharmacists in preventing medical errors from occurring in the wards in Japan. Thus, we conducted a 1-month survey to elucidate the relationship between the number of errors and working hours of pharmacists in the ward, and verified whether the assignment of clinical pharmacists to the ward would prevent medical errors between October 1-31, 2009. Questionnaire items for the pharmacists at 42 national university hospitals and a medical institute included the total and the respective numbers of medication-related errors, beds and working hours of pharmacist in 2 internal medicine and 2 surgical departments in each hospital. Regardless of severity, errors were consecutively reported to the Medical Security and Safety Management Section in each hospital. The analysis of errors revealed that longer working hours of pharmacists in the ward resulted in less medication-related errors; this was especially significant in the internal medicine ward (where a variety of drugs were used) compared with the surgical ward. However, the nurse assignment mode (nurse/inpatients ratio: 1 : 7-10) did not influence the error frequency. The results of this survey strongly indicate that assignment of clinical pharmacists to the ward is critically essential in promoting medication safety and efficacy.

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lymphocyte immunosuppressant sensitivity test (LIST) can predict the pharmacological efficacy of immunosuppressive agents. We herein estimated the mycophenolic acid efficacy using LIST before and 1, 3, and 12 months after the operation in 15 renal transplant recipients. The pharmacological efficacy of mycophenolic acid as assessed before transplantation showed small individual variations, whereas the variability greatly increased at 1 and 3 months after transplantation. Furthermore, the individual IC50 variation among these subjects at 1-year after operation was closely similar to that observed before surgery. No significant implications of these individual differences in the mycophenolic acid sensitivity were noted in regard to the clinical courses of these recipients.

DOI： 10.3109/08923970903490478

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lymphocyte immunosuppressant-sensitivity test (LIST) has been reported extensively as being able to estimate the pharmacological efficacy of immunosuppressive drugs in individual patients. This study measured the IC50 values for 6 drugs, cyclosporine, tacrolimus, methylprednisolone, 6-mercaptopurine, mycophenolic acid, and mizoribine, against mitogen-induced proliferation of peripheral-blood lymphocytes in 29 renal transplant recipients. We also examined relationship between the IC50 values and 4 factors; age, duration of dialysis, percentage of lymphocytes in total white blood cells, and blastogenesis stimulation index by mitogen. There were no significant correlations between the IC50 values and these factors, except that the tacrolimus IC50 value was correlated weakly with the stimulation index (p<0.05, r=-0.429). It was concluded that the pharmacological efficacy of immunosuppressive drugs cannot be inferred from the patient characteristics or their laboratory data. LIST is an effective method to elucidate the pharmacodynamic properties of immunosuppressive agents in individual renal transplant recipients without being influenced by the recipient clinical data.

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本緩和医療薬学会  

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)東京医学社  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J01814&link_issn=&doc_id=20220824100044&doc_link_id=10.24479%2Fohns.0000000284&url=https%3A%2F%2Fdoi.org%2F10.24479%2Fohns.0000000284&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J01461&link_issn=&doc_id=20220407010036&doc_link_id=8862&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8862&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J01461&link_issn=&doc_id=20220407010094&doc_link_id=8862&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8862&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(一社)日本栄養治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本エイズ学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J01461&link_issn=&doc_id=20210413600034&doc_link_id=8861&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8861&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2020&ichushi_jid=J04451&link_issn=&doc_id=20200812230002&doc_link_id=%2Fdg4hppha%2F2020%2F005608%2F002%2F0869-0874%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg4hppha%2F2020%2F005608%2F002%2F0869-0874%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本病院薬剤師会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臨床腫瘍薬学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臨床腫瘍薬学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2020&ichushi_jid=J01461&link_issn=&doc_id=20200406480034&doc_link_id=8860&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8860&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(一社)日本臨床腎移植学会  

researchmap

記述言語：日本語   出版者・発行元：新潟医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2019&ichushi_jid=J00990&link_issn=&doc_id=20200819040001&doc_link_id=%2Fdg3nigta%2F2019%2F013309%2F001%2F0311-0314%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2019%2F013309%2F001%2F0311-0314%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本手術医学会  

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臨床腎移植学会  

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医療情報学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本腎臓病薬物療法学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2018&ichushi_jid=J01461&link_issn=&doc_id=20180328030034&doc_link_id=8787&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8787&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医療情報学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本腎臓病薬物療法学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2017&ichushi_jid=J01461&link_issn=&doc_id=20170330010034&doc_link_id=8791&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8791&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：(公社)日本化学療法学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)医薬品相互作用研究会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本化学療法学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2016&ichushi_jid=J01461&link_issn=&doc_id=20160408010034&doc_link_id=8785&url=https%3A%2F%2Fmol.medicalonline.jp%2Flibrary%2Febooks%2Fdetail%3Fid%3D8785&type=MedicalOnline%28%E9%9B%BB%E5%AD%90%E6%9B%B8%E7%B1%8D%29&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00023_2.gif

記述言語：日本語   出版者・発行元：新潟県医師会  

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本エイズ学会  

researchmap

記述言語：日本語   出版者・発行元：新潟医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2015&ichushi_jid=J00990&link_issn=&doc_id=20160414040009&doc_link_id=%2Fdg3nigta%2F2015%2Fs12911%2F003%2F0700-0700%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2015%2Fs12911%2F003%2F0700-0700%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本手術医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本医療薬学会  

DOI： 10.20825/amjsphcs.25.0_241

CiNii Article

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2014&ichushi_jid=J03926&link_issn=&doc_id=20140909090010&doc_link_id=%2Fca3organ%2F2014%2F002102%2F012%2F0182-0186%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fca3organ%2F2014%2F002102%2F012%2F0182-0186%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臨床腎移植学会  

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2013&ichushi_jid=J06262&link_issn=&doc_id=20131218480015&doc_link_id=%2Fem0sfcrt%2F2013%2F000102%2F015%2F0209-0213%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fem0sfcrt%2F2013%2F000102%2F015%2F0209-0213%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本エイズ学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)医薬品相互作用研究会  

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

So far, more than 82,000 protein structures have been reported in the Protein Data Bank, but the driving force and structures that allow for protein functions have not been elucidated at the atomic level for even one protein. We have been able to clarify that the inter-subunit hydrophobic interaction driving the electrostatic opening of the pore in aquaporin 0 (AQP0). Aquaporins are membrane channels for water and small non-ionic solutes found in animals, plants, and microbes. The structures of aquaporins have high homology and consist of homotetramers, each monomer of which has one pore for a water channel. Each pore has two narrow portions: one is the narrowest constriction region consisting of aromatic residues and an arginine (ar/R), and another is two asparagine-proline-alanine (NPA) homolog portions. Here we show that an inter-subunit hydrophobic interaction in AQP0 drives a stick portion consisting of four amino acids toward the pore and the tip of the stick portion, consisting of a nitrogen atom, opens the pore: that movement is the swing mechanism (this http URL). The energetics and conformational change of amino acids participating in the swing mechanism confirm this view. The swing mechanism in which inter-subunit hydrophobic interactions in the tetramer drive the on-off switching of the pore explains why aquaporins consist of tetramers. Here, we report that experimental and molecular dynamics findings using various mutants support this view of the swing mechanism. The finding that mutants of amino acids in AQP2 corresponding to the stick of the swing mechanism cause severe recessive nephrogenic diabetes insipidus (NDI) demonstrates the critical role of the swing mechanism for the aquaporin function. We report first that the inter-subunit hydrophobic interaction in aquaporin 0 drives the electrostatic opening of the aquaporin pore at the atomic level.

arXiv

researchmap

その他リンク： https://arxiv.org/pdf/1304.5898v1

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2013&ichushi_jid=J03926&link_issn=&doc_id=20130405220006&doc_link_id=%2Fca3organ%2F2013%2F002001%2F006%2F0045-0051%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fca3organ%2F2013%2F002001%2F006%2F0045-0051%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2012&ichushi_jid=J03926&link_issn=&doc_id=20121026230053&doc_link_id=10.11378%2Forganbio.19.223&url=https%3A%2F%2Fdoi.org%2F10.11378%2Forganbio.19.223&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2012&ichushi_jid=J03926&link_issn=&doc_id=20120921120018&doc_link_id=%2Fca3organ%2F2012%2F001901%2F020%2F0103-0106%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fca3organ%2F2012%2F001901%2F020%2F0103-0106%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

新潟大学医歯学総合病院薬剤部では、腎移植患者に対して服薬指導や薬力学的な薬効評価のための免疫抑制薬の感受性試験を実施している。また、テーラーメード医療進展のために、新たな免疫能の評価法であるImmuKnowの実施も検討している。腎移植後の免疫抑制療法は、複数からなる免疫抑制薬から構成されており、移植時期によって投与量も変化することから、腎移植患者に対する服薬指導は移植に対して専門的な知識を持つ薬剤師が担当すべきである。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J03926&link_issn=&doc_id=20110817210004&doc_link_id=10.11378%2Forganbio.18.47&url=https%3A%2F%2Fdoi.org%2F10.11378%2Forganbio.18.47&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2011&ichushi_jid=J01465&link_issn=&doc_id=20110228260009&doc_link_id=%2Fan1yakgl%2F2011%2F005303%2F012%2F0355-0361%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2011%2F005303%2F012%2F0355-0361%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：英語  

Distamycin A (Dst) is an antibiotic which binds to the minor groove of double-stranded DNA at A/T-rich regions. We have examined the affinity and mode of Dst binding to DNA duplexes containing a conserved A/T core and variable terminal A/T regions by using circular dichroism spectroscopy. The observed circular dichroism spectra were analyzed by singular value decomposition and fitted to a two-step binding model. The result clearly shows a correlation between the affinity for Dst and the preference for Dst-DNA 1:1 binding over 2:1 binding. The A/T stretches that prefer 1:1 binding form high-affinity 1:1 complexes, whereas those preferring 2:1 binding form stable 2:1 complex with low overall affinities. The terminal A/T residues of the Dst binding region play an important role in the stabilization/destabilization of the 1:1 and 2:1 complexes, resulting in a terminal residue-dependent variation of the binding affinity and the binding mode preference.

DOI： 10.1016/j.bpc.2010.03.014

PubMed

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(株)日本医学館  

researchmap

記述言語：英語  

Lactoperoxidase (LPO), a mammalian secretory heme peroxidase, catalyzes the oxidation of thiocyanate by hydrogen peroxide to produce hypothiocyanate, an antibacterial agent. Although LPO is known to be activated at acidic pH and in the presence of iodide, the structural basis of the activation is not well understood. We have examined the effects of pH and iodide concentration on the catalytic activity and the structure of LPO. Electrochemical and colorimetric assays have shown that the catalytic activity is maximized at pH 4.5. The heme Soret absorption band exhibits a small red-shift at pH 5.0 upon acidification, which is ascribable to a structural transition from a neutral to an acidic form. Resonance Raman spectra suggest that the heme porphyrin core is slightly contracted and the Fe-His bond is strengthened in the acidic form compared to the neutral form. The structural change of LPO upon activation at acidic pH is similar to that observed for myeloperoxidase, another mammalian heme peroxidase, upon activation at neutral pH. Binding of iodide enhances the catalytic activity of LPO without affecting either the optimum pH of activity or the heme structure, implying that the iodide binding occurs at a protein site away from the heme-linked protonation site.

DOI： 10.1002/bip.21308

PubMed

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：ライフサイエンス出版(株)  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2009&ichushi_jid=J00822&link_issn=&doc_id=20090721220020&doc_link_id=issn%3D0386-8109%26volume%3D43%26issue%3D7%26spage%3D802&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0386-8109%26volume%3D43%26issue%3D7%26spage%3D802&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

記述言語：日本語   出版者・発行元：(株)メディカ出版  

researchmap

記述言語：英語  

The BM2 protein of influenza B virus forms a transmembrane proton channel essential for the virus infection. We investigated the structure and mechanism of the BM2 proton channel by using a 31-mer peptide (BM2-TMP) representing the putative transmembrane domain of BM2, with special focus on His19, Trp23 and His27. Like the full-length protein, BM2-TMP formed a transmembrane proton channel activated at acidic pH with a midpoint of transition at pH 6.4 +/- 0.1. Mutation of His19 to Ala almost abolished the channel activity, whereas the His27-to-Ala mutant retained partial activity. The proton selectivity of the channel was lost upon substitution of Phe for Trp23. Comparison of CD, fluorescence and Raman spectra measured for wild-type and mutated BM2-TMP at varied pH showed the pK(a) of the imidazole ring to be approximately 6.5 for His19 and approximately 7.6 for His27. Analysis of the pH-dependent fluorescence and Raman intensities suggested the occurrence of cation-pi interaction between the protonated imidazole ring of His and the indole ring of Trp. The His19-Trp23 cation-pi interaction below pH 6.5 is likely to trigger the opening of the proton channel, whereas His27 is not essential but enhances the channel activity through interaction with Trp23, which constitutes the proton-selective gate.

DOI： 10.1093/jb/mvp009

PubMed

researchmap

記述言語：英語  

The cation-pi interaction, a noncovalent interaction of electrostatic nature between a cation and an electron-rich pi system, is increasingly recognized as an important force that influences the structures and functions of molecules including proteins. Unlike other metal cations, the transition metal cation Cu2+ is not regarded to take part in a cation-pi interaction because Cu2+ tends to oxidize the pi electron system, in particular that of Trp, and to introduce covalency in the metal-pi electron interaction. This paper reports the first spectral evidence for the cation-pi interaction between Cu2+ and Trp. The Cu2+ ion bound to the amino N-terminal Cu2+/Ni2+ binding motif composed of three amino acid residues interacts with the indole ring of the fourth Trp residue in a noncovalent manner. The Cu2+-Trp interaction produces a distinct negative band at 223 nm in circular dichroism (CD), which disappears upon mutation or depletion of the Trp residue or upon replacement of the Cu2+ ion by Ni2+. In UV absorption, a pair of negative/positive intensity changes is generated at 222/231 nm by the Cu2+-Trp interaction, being consistent with the previous observations on the indole ring interacting with K+ or a cationic His imidazole ring. The negative CD band around 223 nm is characteristic of the Cu2+-Trp pair and may be useful as a marker of the Cu2+-Trp cation-pi interaction. Coordination of negatively charged ligands to Cu2+ is suggested to be important for the cation to be involved in a cation-pi interaction.

DOI： 10.1021/ja807010f

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：日本ジェネリック医薬品・バイオシミラー学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)医薬品相互作用研究会  

researchmap

記述言語：日本語   出版者・発行元：応用薬理研究会  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2008&ichushi_jid=J01465&link_issn=&doc_id=20080402130005&doc_link_id=%2Fan1yakgl%2F2008%2F005004%2F008%2F0561-0564%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2008%2F005004%2F008%2F0561-0564%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)ライフ・サイエンス  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2008&ichushi_jid=J01465&link_issn=&doc_id=20080109190005&doc_link_id=%2Fan1yakgl%2F2008%2F005001%2F011%2F0053-0058%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2008%2F005001%2F011%2F0053-0058%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2008&ichushi_jid=J01465&link_issn=&doc_id=20080109190015&doc_link_id=%2Fan1yakgl%2F2008%2F005001%2F022%2F0135-0142%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2008%2F005001%2F022%2F0135-0142%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(公財)日本腎臓財団  

researchmap

記述言語：日本語   出版者・発行元：(株)日本医学館  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J01465&link_issn=&doc_id=20070904150015&doc_link_id=%2Fan1yakgl%2F2007%2F004909%2F019%2F1389-1393%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2007%2F004909%2F019%2F1389-1393%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：新潟医学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J00990&link_issn=&doc_id=20071115080001&doc_link_id=%2Fdg3nigta%2F2007%2F012108%2F001%2F0427-0431%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2007%2F012108%2F001%2F0427-0431%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(NPO)日本医療マネジメント学会  

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J01465&link_issn=&doc_id=20070502360012&doc_link_id=%2Fan1yakgl%2F2007%2F004905%2F017%2F0733-0739%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2007%2F004905%2F017%2F0733-0739%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J00821&link_issn=&doc_id=20070307040024&doc_link_id=%2Faf5thrpc%2F2007%2F008903%2F024%2F0557-0560%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Faf5thrpc%2F2007%2F008903%2F024%2F0557-0560%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本医療薬学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J03520&link_issn=&doc_id=20070119430011&doc_link_id=%2Fdb5pharm%2F2007%2F003301%2F011%2F0070-0077%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdb5pharm%2F2007%2F003301%2F011%2F0070-0077%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J01465&link_issn=&doc_id=20070110200009&doc_link_id=%2Fan1yakgl%2F2007%2F004901%2F012%2F0093-0096%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2007%2F004901%2F012%2F0093-0096%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2006&ichushi_jid=J01465&link_issn=&doc_id=20060907170013&doc_link_id=%2Fan1yakgl%2F2006%2F004810%2F018%2F1575-1578%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2006%2F004810%2F018%2F1575-1578%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本医薬品情報学会  

researchmap

記述言語：日本語   出版者・発行元：(NPO)日本医療マネジメント学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2006&ichushi_jid=J01316&link_issn=&doc_id=20060612410013&doc_link_id=10.14894%2Ffaruawpsj.42.6_600&url=https%3A%2F%2Fdoi.org%2F10.14894%2Ffaruawpsj.42.6_600&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：日本語   出版者・発行元：(株)医薬ジャーナル社  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2006&ichushi_jid=J01465&link_issn=&doc_id=20060512250015&doc_link_id=%2Fan1yakgl%2F2006%2F004805%2F015%2F0717-0721%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2006%2F004805%2F015%2F0717-0721%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：英語  

The ClC chloride channels control the ionic composition of the cytoplasm and the volume of cells, and regulate electrical excitability. Recently, it has been proposed that prokaryotic ClC channels are H+-Cl- exchange transporter. Although X-ray and molecular dynamics (MD) studies of bacterial ClC channels have investigated the filter open-close and ion permeation mechanism of channels, details have remained unclear. We performed MD simulations of ClC channels involving H+, Na+, K+, or H3O+ in the intracellular region to elucidate the open-close mechanism, and to clarify the role of H+ ion an H+-Cl- exchange transporter. Our simulations revealed that H+ and Na+ caused channel opening and the passage of Cl- ions. Na+ induced a bead-like string of Cl- -Na+-Cl--Na+-Cl- ions to form and permeate through ClC channels to the intracellular side with the widening of the channel pathway.

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(株)じほう  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2006&ichushi_jid=J01465&link_issn=&doc_id=20060116010004&doc_link_id=%2Fan1yakgl%2F2006%2F004801%2F010%2F0037-0043%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2006%2F004801%2F010%2F0037-0043%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2006&ichushi_jid=J01461&link_issn=&doc_id=20060929300002&doc_link_id=%2Faf5prcpl%2F2006%2F005701%2F002%2F0009-0013%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Faf5prcpl%2F2006%2F005701%2F002%2F0009-0013%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本移植学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2005&ichushi_jid=J00083&link_issn=&doc_id=20060412090008&doc_link_id=%2Fcl8isoke%2F2005%2F004006%2F008%2F0533-0538%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcl8isoke%2F2005%2F004006%2F008%2F0533-0538%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：(一社)日本クリニカルパス学会  

researchmap

記述言語：日本語   出版者・発行元：(株)南山堂  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本クリニカルパス学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本臓器保存生物医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)医薬品相互作用研究会  

researchmap

記述言語：英語  

The physiological function of the prion protein (PrP) remains enigmatic despite its established involvement in the pathogenesis of spongiform encephalopathies. PrP is a glycolipid-anchored membrane protein, which constitutively recycles between the cell surface and an endosomal compartment. The N-terminal region of PrP contains a four tandem repeat (OP4) of the octapeptide PHGGGWGQ (OP) that binds and reduces Cu(II) ions. We have examined the kinetic properties of the OP4-mediated Cu(II) reduction and found that OP4 exhibits the highest reduction activity around pH 6.5, close to the pH in early endosomes. All four OP units and at least one tryptophan side chain are essential for Cu(II) reduction. The reaction is described by an uncompetitive substrate inhibition mechanism involving a 1:1 Cu(II)-OP4 active intermediate. Structural analysis by Raman spectroscopy has revealed that the Cu(II) ion is coordinated by four histidine Ntau atoms in the active intermediate and the feasibility of formation of this intermediate correlates with the Cu(II) reduction over a pH range from 5.0 to 8.2. Molecular mechanics calculations suggest that two tryptophan residues of OP4 are located near the Cu(II) site, being consistent with the importance of redox-active tryptophan in the Cu(II) reduction. PrP has been proposed to capture Cu(II) ions in the extracellular space and release them in the endosome. The results of this study strongly suggest that PrP also plays a role in the reduction of captured Cu(II) ions prior to their transfer to Cu(I)-specific intracellular copper trafficking proteins.

PubMed

researchmap

記述言語：英語  

DOI： 10.1021/bi049767k

Web of Science

PubMed

CiNii Article

researchmap

記述言語：英語  

DOI： 10.1021/bi049767k

Web of Science

PubMed

CiNii Article

researchmap

記述言語：英語  

DOI： 10.1016/S0014-5793(04)00114-0

Web of Science

researchmap

記述言語：英語  

DOI： 10.1016/S0014-5793(04)00114-0

Web of Science

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

記述言語：英語  

DOI： 10.1002/jrs.899

Web of Science

researchmap

記述言語：英語  

DOI： 10.1021/jp0124185

Web of Science

CiNii Article

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）  

Web of Science

researchmap

記述言語：英語  

DOI： 10.1002/bip.10081

Web of Science

PubMed

CiNii Article

researchmap

記述言語：英語  

DOI： 10.1002/bip.10081

Web of Science

PubMed

CiNii Article

researchmap

記述言語：英語  

DOI： 10.1016/S0022-2860(01)00808-0

Web of Science

CiNii Article

researchmap

researchmap

researchmap

記述言語：英語  

DOI： 10.1002/(SICI)1097-4555(199908)30:8<623::AID-JRS407>3.0.CO;2-9

Web of Science

researchmap

記述言語：英語  

DOI： 10.1016/S0022-2860(98)00301-9

Web of Science

researchmap

記述言語：英語  

Web of Science

researchmap

記述言語：英語  

Web of Science

researchmap

記述言語：英語  

DOI： 10.1021/ja00077a005

Web of Science

CiNii Article

researchmap

記述言語：英語  

DOI： 10.2183/pjab.69.224

Web of Science

CiNii Article

researchmap

記述言語：英語   掲載種別：記事・総説・解説・論説等（学術雑誌）  

DOI： 10.1111/j.1751-1097.1993.tb02307.x

Web of Science

CiNii Article

researchmap

記述言語：英語   掲載種別：記事・総説・解説・論説等（学術雑誌）  

DOI： 10.1021/ja00009a071

Web of Science

CiNii Article

researchmap

記述言語：英語  

DOI： 10.1016/0022-2860(91)87129-6

Web of Science

researchmap

記述言語：英語  

DOI： 10.1021/ic00310a012

Web of Science

CiNii Article

researchmap

記述言語：日本語   出版者・発行元：(社)日本化学会  

researchmap